Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Dysbindin-1 and schizophrenia: from genetics to neuropathology
Michael J. Owen, … , Nigel M. Williams, Michael C. O’Donovan
Michael J. Owen, … , Nigel M. Williams, Michael C. O’Donovan
Published May 1, 2004
Citation Information: J Clin Invest. 2004;113(9):1255-1257. https://doi.org/10.1172/JCI21470.
View: Text | PDF
Commentary

Dysbindin-1 and schizophrenia: from genetics to neuropathology

  • Text
  • PDF
Abstract

The gene encoding dysbindin-1 has recently been implicated in susceptibility to schizophrenia. In this issue of the JCI, Talbot et al. show that, contrary to expectations, dysbindin-1 is located presynaptically in glutamatergic neurons and is reduced at these locations in schizophrenia . Further studies of dysbindin-1 and the proteins with which it interacts can be expected to throw light on the pathogenesis of schizophrenia.

Authors

Michael J. Owen, Nigel M. Williams, Michael C. O’Donovan

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of a glutamatergic synapse. Several genes have ...
Schematic representation of a glutamatergic synapse. Several genes have been implicated in susceptibility to schizophrenia that can potentially impact on glutamate (Glu) synaptic function including dysbindin-1, neuregulin 1 (NRG1), G72, D-amino acid oxidase (DAAO), and regulator of G protein signalling 4 (RGS4). Dysbindin-1 may influence VGlutT-1 expression, synthesis, or degradation and is a component of the postsynaptic density (PSD). NRG1 is present in glutamate synaptic vesicles, regulates expression of N-methyl-D-aspartate receptors (NMDARs), activates ErbB4 receptors, which colocalize with NMDARs, and interacts with the PSD. G72 interacts with DAAO, which oxidizes D-serine, an endogenous modulator of NMDARs. RGS4 is a negative regulator of G protein_coupled receptors, especially the metabotropic glutamate receptor 5 (mGluR5), via its effects on the G protein Gq. Figure modified with permission from The Lancet (7).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts